Is Teva’s US Decline In Q3 Evidence Of A Broader Downward Trend?
Third Quarter Numbers Follow Sandoz’ View Of ‘Challenging Environment’
Teva faced questions about the current environment in the US for generics, following weakness in its numbers and in those of rival Sandoz during the third quarter. Management remains “very committed to the US generics segment,” after sales dropped by 7%.
